Plasmalogens and Alzheimer’s disease: a review
Abstract Growing evidence suggests that ethanolamine plasmalogens (PlsEtns), a subtype of phospholipids, have a close association with Alzheimer’s disease (AD). Decreased levels of PlsEtns have been commonly found in AD patients, and were correlated with cognition deficit and severity of disease. Li...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2019-04-01
|
| Series: | Lipids in Health and Disease |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s12944-019-1044-1 |
| _version_ | 1828466125413810176 |
|---|---|
| author | Xiao Q. Su Junming Wang Andrew J. Sinclair |
| author_facet | Xiao Q. Su Junming Wang Andrew J. Sinclair |
| author_sort | Xiao Q. Su |
| collection | DOAJ |
| description | Abstract Growing evidence suggests that ethanolamine plasmalogens (PlsEtns), a subtype of phospholipids, have a close association with Alzheimer’s disease (AD). Decreased levels of PlsEtns have been commonly found in AD patients, and were correlated with cognition deficit and severity of disease. Limited studies showed positive therapeutic outcomes with plasmalogens interventions in AD subjects and in rodents. The potential mechanisms underlying the beneficial effects of PlsEtns on AD may be related to the reduction of γ–secretase activity, an enzyme that catalyzes the synthesis of β-amyloid (Aβ), a hallmark of AD. Emerging in vitro evidence also showed that PlsEtns prevented neuronal cell death by enhancing phosphorylation of AKT and ERK signaling through the activation of orphan G-protein coupled receptor (GPCR) proteins. In addition, PlsEtns have been found to suppress the death of primary mouse hippocampal neuronal cells through the inhibition of caspase-9 and caspase-3 cleavages. Further in-depth investigations are required to determine the signature molecular species of PlsEtns associated with AD, hence their potential role as biomarkers. Clinical intervention with plasmalogens is still in its infancy but may have the potential to be explored for a novel therapeutic approach to correct AD pathology and neural function. |
| first_indexed | 2024-12-11T03:44:33Z |
| format | Article |
| id | doaj.art-bb4bc6ffb1e44359a73308b75fc85c42 |
| institution | Directory Open Access Journal |
| issn | 1476-511X |
| language | English |
| last_indexed | 2024-12-11T03:44:33Z |
| publishDate | 2019-04-01 |
| publisher | BMC |
| record_format | Article |
| series | Lipids in Health and Disease |
| spelling | doaj.art-bb4bc6ffb1e44359a73308b75fc85c422022-12-22T01:22:03ZengBMCLipids in Health and Disease1476-511X2019-04-0118111010.1186/s12944-019-1044-1Plasmalogens and Alzheimer’s disease: a reviewXiao Q. Su0Junming Wang1Andrew J. Sinclair2Institute for Health and Sport, Victoria UniversityDepartment of Pathology, University of Mississippi Medical CentreFaculty of Health, Deakin UniversityAbstract Growing evidence suggests that ethanolamine plasmalogens (PlsEtns), a subtype of phospholipids, have a close association with Alzheimer’s disease (AD). Decreased levels of PlsEtns have been commonly found in AD patients, and were correlated with cognition deficit and severity of disease. Limited studies showed positive therapeutic outcomes with plasmalogens interventions in AD subjects and in rodents. The potential mechanisms underlying the beneficial effects of PlsEtns on AD may be related to the reduction of γ–secretase activity, an enzyme that catalyzes the synthesis of β-amyloid (Aβ), a hallmark of AD. Emerging in vitro evidence also showed that PlsEtns prevented neuronal cell death by enhancing phosphorylation of AKT and ERK signaling through the activation of orphan G-protein coupled receptor (GPCR) proteins. In addition, PlsEtns have been found to suppress the death of primary mouse hippocampal neuronal cells through the inhibition of caspase-9 and caspase-3 cleavages. Further in-depth investigations are required to determine the signature molecular species of PlsEtns associated with AD, hence their potential role as biomarkers. Clinical intervention with plasmalogens is still in its infancy but may have the potential to be explored for a novel therapeutic approach to correct AD pathology and neural function.http://link.springer.com/article/10.1186/s12944-019-1044-1PlasmalogensAlzheimer’s diseaseBiomarkerTherapeutic efficacyMechanisms of action |
| spellingShingle | Xiao Q. Su Junming Wang Andrew J. Sinclair Plasmalogens and Alzheimer’s disease: a review Lipids in Health and Disease Plasmalogens Alzheimer’s disease Biomarker Therapeutic efficacy Mechanisms of action |
| title | Plasmalogens and Alzheimer’s disease: a review |
| title_full | Plasmalogens and Alzheimer’s disease: a review |
| title_fullStr | Plasmalogens and Alzheimer’s disease: a review |
| title_full_unstemmed | Plasmalogens and Alzheimer’s disease: a review |
| title_short | Plasmalogens and Alzheimer’s disease: a review |
| title_sort | plasmalogens and alzheimer s disease a review |
| topic | Plasmalogens Alzheimer’s disease Biomarker Therapeutic efficacy Mechanisms of action |
| url | http://link.springer.com/article/10.1186/s12944-019-1044-1 |
| work_keys_str_mv | AT xiaoqsu plasmalogensandalzheimersdiseaseareview AT junmingwang plasmalogensandalzheimersdiseaseareview AT andrewjsinclair plasmalogensandalzheimersdiseaseareview |